Whats new

Whats new.

CLSA - Immutep: Defining year. Cash-runway through late stage head & neck readout and Lung Ph3 start. Retain Buy, A$1.25 tgt (Andrew Paine)

March 8th 2023

For a copy of this analyst report please contact your CLSA advisor

Go back